This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2002;288:1579.

	Since this article does not have an abstract, we have provided the first 63 words of the full text and any section headings.

The FDA has posted information on the Internet about the use of its authority in instances when it appears that a clinical investigator's misconduct poses ongoing risk to the safety and welfare of human subjects in a study involving human drug or biological products. For full text, see http://www.fda.gov/cber/guidelines.htm.

AUTHOR INFORMATION

Written inquiries may be directed to Office of the Commissioner of Food and Drugs, HF-1, Room 14-71, 5600 Fishers Ln, Rockville, MD 20857.

Lester M. Crawford, Jr, DVM, PhD
Deputy Commissioner
US Food and Drug Administration